Tyrosine kinase inhibitors (TKI) are the optimal first-line treatment of patients with stage IV NSCLC harboring TKI-sensitive EGFR mutations (Maemondo et al. 2010; Ramalingam et al. 2020; Rosell et al. 2012; Sequist et al. 2013; Wu et al. 2014, 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.